Tue Sep 10 15:57:00 UTC 2024: ## Eli Lilly Announces Promising Results for Once-Weekly Insulin in Type 1 Diabetes

**INDIANAPOLIS, Sept. 10, 2024** – Eli Lilly and Company (NYSE: LLY) has announced positive results from its QWINT-5 Phase 3 trial, showcasing the efficacy of once-weekly insulin efsitora alfa (efsitora) in adults with Type 1 diabetes. The study, published in *The Lancet* and presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, compared efsitora to once-daily insulin degludec, a commonly used insulin.

Efsitora achieved the primary endpoint of non-inferior A1C reduction at week 26. The trial demonstrated that efsitora reduced A1C by 0.53% compared to 0.59% for insulin degludec, resulting in an A1C of 7.37% and 7.32% respectively.

Key secondary endpoints revealed that time in range, measured by continuous glucose monitoring (CGM), was similar between the two treatments. Additionally, the estimated combined rates of patient-reported clinically significant hypoglycemic events were comparable.

“This new data shows that with one dose a week of basal insulin, efsitora was able to achieve similar A1C reduction as taking an injection of one of the most used background insulins every day,” stated Dr. Richard Bergenstal, executive director of the International Diabetes Center, HealthPartners Institute. “I look forward to further evaluation of these data, including ways to minimize hypoglycemia, so once-weekly insulin can be one option for personalizing the management of Type 1 diabetes.”

While efsitora exhibited a higher rate of severe hypoglycemic events in the initial 12 weeks, the incidence declined after this period. Overall, the occurrence of treatment-emergent adverse events was comparable between the two treatment groups.

“These results underscore the potential of efsitora to help some people living with Type 1 diabetes lower their A1C with only one basal insulin injection per week,” said Dr. Jeff Emmick, senior vice president, product development at Lilly. “With the data we have seen from our phase 3 program so far, we are confident in efsitora’s potential to transform diabetes care.”

The QWINT-5 study enrolled over 692 participants across various countries and is part of a larger global clinical development program for efsitora, which has enrolled over 4,000 individuals with Type 1 or Type 2 diabetes.

This news presents a significant development in the management of Type 1 diabetes, offering a potential for a more convenient and potentially less burdensome treatment option for patients. Further research and regulatory approval are necessary before efsitora becomes widely available.

Read More